Sjogren's Syndrome World Market Study, 2020 - Key Marketed & Pipeline Drugs, Clinical Trials, Upcoming Events, Patent Information, 10-Year Disease Prevalence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Sjögren's Syndrome" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight covers the Sjogren's Syndrome market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

  • This research estimates that in 2018, there were approximately 2.3 million prevalent cases of primary Sjogren's syndrome worldwide, and forecasts that number to increase to 2.5 million prevalent cases by 2027.
  • Primary Sjogren's syndrome has a female predominance. Globally, the publisher estimates that in 2018, 90.4% of cases aged 15 years and over were female.
  • Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjogren's syndrome.
  • The majority of industry-sponsored drugs in active clinical development for Sjogren's syndrome are in Phase II, with only one drug in Phase III.
  • Therapies in development for Sjogren's syndrome focus on a wide variety of targets. The pipeline drugs for Sjogren's syndrome are administered via the oral, intravenous, and subcutaneous routes.
  • The only high-impact upcoming event in the Sjogren's syndrome space is topline Phase II trial results for Benlysta SC. The overall likelihood of approval of a Phase I arthritis asset is 9.9%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9 years in the overall autoimmune/immunology space.
  • There have been only four licensing and asset acquisition deals involving Sjogren's syndrome drugs during 2015-2020. The exclusive licensing and collaboration agreement between Eli Lilly and Hanmi for $690m, regarding the development and commercialization of Hanmi's oral BTK inhibitor HM71224 for the treatment of autoimmune and other diseases, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjogren's syndrome have been in the early and mid-phases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV.
  • The US has the highest number of Sjogren's syndrome clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the Sjogren's syndrome space is dominated by completed trials. Novartis has the highest number of completed clinical trials for Sjogren's syndrome, with eight trials.
  • Novartis leads the industry sponsors with the highest overall number of clinical trials for Sjogren's syndrome, followed by BristolMyers Squibb.

Companies Mentioned

  • Advanz
  • BristolMyers Squibb
  • Eisai
  • Eli Lilly
  • Hanmi
  • Novartis

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Dry Eyes
  • Dry Mouth
  • Other Glandular Manifestations
  • Extraglandular Manifestations

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Iscalimab for Sjogren's Syndrome (January 23, 2020)
  • Mutliple Drugs for Sjogren's Syndrome (October 24, 2019)
  • RSLV-132 for Sjogren's Syndrome (June 13, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Advanz Obtains Two Commercial Products from Eisai

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by Status
  • Sponsors by Phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

List of Figures

Figure 1: Trends in Prevalent Cases of Primary Sjogren's Syndrome, 2018-2027

Figure 2: Overview of Pipeline Drugs for Sjogren's Syndrome in the US

Figure 3: Pipeline Drugs for Sjogren's Syndrome, by Company

Figure 4: Pipeline Drugs for Sjogren's Syndrome, by Drug Type

Figure 5: Pipeline Drugs for Sjogren's Syndrome, by Classification

Figure 6: Iscalimab for Sjogren's Syndrome (January 23, 2020): Phase II - Primary Sjogren

Figure 7: RSLV-132 for Sjogren's Syndrome (June 13, 2019): Phase II - Study 132-04

Figure 8: Key Upcoming Events in Sjogren's Syndrome

Figure 9: Probability of Success in the Sjogren's Syndrome Pipeline

Figure 10: Licensing and Asset Acquisition Deals in Sjogren's Syndrome, 2015-2020

Figure 11: Parent Patents in Sjogren's Syndrome

Figure 12: Clinical Trials in Sjogren's Syndrome

Figure 13: Top 10 Drugs for Clinical Trials in Sjogren's Syndrome

Figure 14: Top 10 Companies for Clinical Trials in Sjogren's Syndrome

Figure 15: Trial Locations in Sjogren's Syndrome

Figure 16: Sjogren's Syndrome Trials Status

Figure 17: Sjogren's Syndrome Trials Sponsors, by Phase

List of Tables

Table 1: Prevalent Cases of Primary Sjogren's Syndrome, 2018-2027

Table 2: Prevalent Cases of Primary Sjogren's Syndrome, by Gender, 2018

Table 3: Prevalence of Primary Sjogren's Syndrome, by Gender, 2018

Table 4: Marketed Drugs for Sjogren's Syndrome

Table 5: Pipeline Drugs for Sjogren's Syndrome in the US

Table 6: Iscalimab for Sjogren's Syndrome (January 23, 2020)

Table 7: Mutliple Drugs for Sjogren's Syndrome (October 24, 2019)

Table 8: RSLV-132 for Sjogren's Syndrome (June 13, 2019)

For more information about this report visit https://www.researchandmarkets.com/r/16cegt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900